|1.||Lefebvre, Hervé: 4 articles (04/2015 - 01/2003)|
|2.||Bockaert, Joël: 4 articles (01/2013 - 01/2004)|
|3.||Lezoualc'h, Frank: 4 articles (04/2009 - 01/2007)|
|4.||Cartier, Dorthe: 4 articles (12/2005 - 03/2002)|
|5.||Kuhn, Jean-Marc: 4 articles (12/2005 - 03/2002)|
|6.||Vaudry, Hubert: 4 articles (12/2005 - 03/2002)|
|7.||Louiset, Estelle: 3 articles (04/2015 - 05/2005)|
|8.||Levy, Finn Olav: 3 articles (06/2013 - 03/2005)|
|9.||Hen, René: 3 articles (01/2010 - 01/2004)|
|10.||Compan, Valérie: 3 articles (01/2010 - 01/2004)|
12/01/2014 - "Adverse effects of previously developed 5-HT4 receptor agonists to treat functional constipation (FC) and constipation IBS (IBS-C) patients have limited their use but have given rise to new and more selective 5-HT4 receptor agonists. "
07/15/2014 - "Taken together, DA-6886 is a highly potent and selective 5-HT4 receptor agonist to accelerate colonic transit in mice, which might be therapeutic agent having a favorable safety profile in the treatment of gastrointestinal motor disorders such as IBS-C and chronic constipation. "
01/01/2001 - "A related class of drugs, the 5-HT4 receptor agonists, is being developed for the treatment of constipation-predominant IBS. "
02/01/2015 - "Prucalopride, a highly selective 5-HT4 receptor agonist, stimulates gastrointestinal motility and has been proven to be effective in the treatment of CC in adults by increasing stool frequency, reducing constipation-related symptoms and improving quality of life (QoL). "
12/01/2013 - "Recently, prucalopride, a highly selective 5-HT4 receptor agonist has been shown to improve the symptoms of chronic constipation and to have a beneficial effect on social and healthcare impact. "
|2.||Irritable Bowel Syndrome (Syndrome, Irritable Bowel)
11/01/1999 - "To investigate the effects of SB-207266-A, a selective 5-HT4 receptor antagonist on rectal sensitivity and small bowel transit in patients with irritable bowel syndrome. "
11/01/1999 - "5-HT4 receptor antagonism in irritable bowel syndrome: effect of SB-207266-A on rectal sensitivity and small bowel transit."
04/01/2005 - "To evaluate the safety/tolerability and efficacy of tegaserod, a 5-HT4 receptor partial agonist, in the treatment of patients with non-diarrhoea irritable bowel syndrome (non-D-IBS) in Switzerland. "
03/01/1999 - "Novartis is developing Zelmac (SDZ-HTF-919), a 5-HT4 receptor partial agonist, which is in phase III clinical trials for the treatment of gastric motility disorders and irritable bowel syndrome (IBS). "
08/01/2011 - "Effect of 5-HT4 receptor agonist mosapride citrate on rectosigmoid sensorimotor function in patients with irritable bowel syndrome."
04/04/1997 - "These results suggest that 5-methoxytryptamine-induced hyperglycemia is mediated by the peripheral 5-HT2A receptor, although it has a high affinity for the 5-HT4 receptor. "
06/20/1996 - "Neither the 5-HT2A receptor antagonist ketanserin nor the 5-HT3/5-HT4 receptor antagonist (3-alpha-tropanyl)-1 H-indole-3-carboxylic acid ester (ICS 205-930) proved effective against mCPP-induced hyperglycemia. "
10/23/1998 - "However, the 5-HT3 and 5-HT4 receptor antagonist, tropisetron, the 5-HT4 receptor antagonist, 2-methoxy-4-amino-5-chloro-benzoic acid 2-(diethylamino) ethyl ester (SDZ 205-557), and the 5-HT2A receptor antagonist, ketanserin, did not affect the p-chloroamphetamine-induced hyperglycemia. "
04/04/1997 - "5-Methoxytryptamine induced a significant hyperglycemia above the dosage of 1 mg/kg. 5-Methoxytryptamine-induced hyperglycemia was antagonized by pretreatment with the 5-HT1 and 5-HT2 receptor antagonist, methysergide, or the 5-HT2A receptor antagonist, ketanserin, whereas the 5-HT3 and 5-HT4 receptor antagonist, tropisetron, and the 5-HT4 receptor antagonist, SDZ 205-557 (2-methoxy-4-amino-5-chloro-benzoic acid 2-(diethylamino) ethyl ester), showed no effect. "
01/14/2004 - "Attenuated response to stress and novelty and hypersensitivity to seizures in 5-HT4 receptor knock-out mice."
08/21/1992 - "5HT1c receptor antagonists (mianserin and cyproheptadine), 5-HT3 receptor antagonist (zacopride) and 5-HT4 receptor antagonist (ICS 205-930) increased the latency of audiogenic seizures and decreased the severity of convulsions in young (20-27 days old) DBA/2 mice. "
12/01/2005 - "In situ hybridization studies showed that 5-HT4 receptor mRNAs were expressed in both zona glomerulosa and zona fasciculata/reticularis of the normal cortex and in groups of APA steroidogenic cells disseminated in the tumor tissues. "
05/01/2005 - "These results show that the hypersensitivity of the tumors to 5-HT was related to tissue expression of an ectopic serotonergic receptor in addition to the eutopic 5-HT4 receptor. "
05/01/2006 - "The present study suggests that a combined 5-HT3-receptor antagonist/5-HT4-receptor agonist, like zacopride, may be useful against both acute and delayed emesis induced by cancer chemotherapy."
|4.||5-HT3 Serotonin Receptors (5 HT3 Receptor)
|5.||5-HT2A Serotonin Receptor (5 HT2A Receptor)
|1.||Drug Therapy (Chemotherapy)